The classification of cutaneous melanoma

Area of Science:

• Dermatology
• Oncology
• Pathology

Background:

• Established clinical and histological classification for cutaneous melanoma, including subtypes like superficial spreading, nodular, and lentigo maligna, and prognostic factors such as tumor thickness, ulceration, and mitotic activity, has been the cornerstone of diagnosis and staging for four decades.
• Despite advancements, no molecular marker has reliably improved melanoma staging or treatment.
• Current staging relies on simple measurements like tumor thickness and assessment of ulceration and mitotic activity.

Purpose of the Study:

• To review the historical and current significance of clinical and histological factors in cutaneous melanoma classification and staging.
• To explore the emerging role of molecular markers and genomic analysis in refining melanoma diagnosis and treatment prediction.

Main Methods:

• Review of historical clinical and histological classification schemes for cutaneous melanoma.
• Analysis of prognostic factors including tumor thickness, ulceration, and mitotic activity.
• Examination of recent mutational analysis correlating genetic findings with established morphological descriptors.

Main Results:

• The foundational classification and prognostic factors for cutaneous melanoma (superficial spreading, nodular, lentigo maligna; thickness, ulceration, mitotic activity) remain critical for current diagnosis and staging.
• Mutational analysis has revealed correlations between specific genetic mutations and these long-standing morphological descriptors.
• No molecular marker has yet proven reliably useful for staging or treatment.

Conclusions:

• The established clinical and histological parameters for cutaneous melanoma continue to be highly relevant for diagnosis and staging.
• Emerging genomic and intra-tumoral expression profiles show promise for future classification schemes, potentially enhancing prediction of therapeutic response.
• Integrating molecular data with histologic findings may lead to more powerful and personalized melanoma management strategies.